Column	Code	Name	Description
A	KOD	SÚKL code	Code of the medicinal product allocated by SÚKL to the presentation of the medicinal product as part of the marketing authorisation (MA) of the medicinal product or allocated to a non-authorised medicinal product included in a specific therapeutic programme, or allocated to food for special medical purposes
B	NAZ	Name of the medicinal product	Name of the medicinal product or of the food for special medical purposes
C	DOP	Medicinal product specification	Medicinal product name supplement, which clearly defines the presentation of the product, consisting of an integration of its route of administration, pharmaceutical form, pack size and strength. This item of the List is further specified under items CESTA, FORMA, BALENI and SILA
D	CESTA	Route of administration	Route of administration
E	FORMA	Pharmaceutical form	Pharmaceutical form
F	BALENI	Pack	Pack size
G	SILA	Strength	The strength of the medicinal product, which shall mean the contents of active substances expressed qualitatively in respect of a unit of dose, volume or weight, depending on the pharmaceutical form.
H	OBAL	Packaging	The immediate packaging of the medicinal product which shall mean such form of packaging which is in immediate contact with the medicinal product.
I	DRZ	MA holder	Marketing authorisation holder's abbreviation. A common implemental index is available for fields DRZ and ZEM DRZ.
J	ZEMDRZ	Holder's country	An abbreviation of the country of the marketing authorisation holder's registered office; for medicinal products included in specific therapeutic programmes and for foods for special medical purposes this shall mean the abbreviation of the country of manufacturer's/importer's registered office. A common implemental index is available for fields DRZ and ZEM DRZ.
K	RC	MA number	Marketing authorisation number, which identifies a group of presentations of a medicinal product for which the marketing authorisation has been issued.
L	SOUBDOV	Parallel import ID	The identification number of parallel import, which is associated with the respective reference product as per MA number; usually in the following format: PI/xxx/tyty
M	T_REG	MA type	Marketing authorisation (type of marketing authorisation – national, MRP, DCP, via centralised procedure, adopted MA, parallel import).
N	S_REG	MA status	Status of the marketing authorisation; the basic values being as follows: **R –** Authorised medicinal product **B –** Following an implemented variation thereto, the product may be marketed for the period of 6 months and used until its expiry date, not exceeding the MA expiry date **Q –** The product could be marketed for the period of 6 months following an implemented code conversion and may be used until its expiry date not exceeding the MA expiry date **F –** Specific therapeutic programme authorised by the Ministry of Health of the Czech Republic upon SÚKL's recommendation **P** – Foods for special medical purposes
O	TCR	Price regulation type	Type of price regulation – applicable values being as follows: **MCV** – Maximum ex-factory price **OP** – Regulation of the profit margin; the factory price is not subjected to regulation pursuant to the Price Regulation of the Ministry of Health.
P	MAXCV	Max. ex-factory price	Maximum ex-factory price of the medicinal product/food for special medical purposes
Q	LEG_CV	Max. price legal base	**P** – An ex lege price decrease, i.e. a price decrease set forth by the law **N** – The stated price is the ex lege established or changed price for which the applicant may place the medicinal product or the food for special medical purposes on the market, if their applications have not been decided on within timelines stipulated by Act No 48/1997 Coll., as amended. This price equals the price specified in the application for maximum price determination or change thereof. This price shall be effective until the executive decision in the matter is issued. **S** – Established or amended via an administrative procedure as per Act No 48/1997 Coll., as amended with the effective date of January 1 2008 **Z** – Established or amended ex lege **M** – Established as per Act No 265/1991 Coll. and Act No 526/1990 Coll., as amended prior to December 31 2007
R	UHR1	Reimbursement	Reimbursement of the medicinal product

S	LEG_UHR1	Reimbursement legal base	**A** – An ex lege (:by law) determined full reimbursement of a medicinal product containing an active substance listed under Section 15, paragraph 4 of Act No 48/1997 Coll., as amended **Z** – Changed ex lege, i.e. changed by law **P** – An ex lege (:by law) transient decrease in reimbursement **V** – The medicinal product is reimbursed as part of reimbursed care referred to in Section 30 of Act No 48/1997 Coll., as amended (applies only to vaccines listed in Section 30 of the above-mentioned Act). The amount of reimbursement shall not exceed the amount of the price of the least economically costly variant of the vaccine specified in field RP3 and, at the same time, the amount of reimbursement shall not, in any case, exceed the value specified in field UHR1. **O** – The reduction of reimbursement within the scope of measures approved by the government in order to safeguard financial stability of the health insurance system pursuant to Section 39i, paragraph 3 of Act No 48/1997 Coll. **S** – Established or amended via an administrative procedure as per Act No 48/1997 Coll., as amended with effective date of January 1 2008 **Z** – Established or amended ex lege **M** – Established as per Act No 265/1991 Coll. and Act No 526/1990 Coll., as amended prior to December 31 2007
T	LIM1	Reporting limit	Method of reporting medicinal products/foods for special medical purposes to the health insurance company. The Czech version of the website provides an implemental index of status values for fields LIM1 and LIM2.
U	OME1	Prescribing doctor's specialisation	Specification of prescription restriction based upon the specialisation of the prescribing doctor. For a single code of the medicinal product/food for special medical purposes it may assume several OME1 values. The Czech version of the website provides an implemental index of status values for fields OME1 and OME2.
V	IND1	Indication restriction flag	Indication restriction (P). An implemental index is available for indication prescription detail (indication or clinical status conditioning the reimbursement of the medicinal product/food for special medical purposes).
W	DET_IND1	Indication restriction detail	Indication or clinical status conditioning the reimbursement of the medicinal product/food for special medical purposes.
X	PUHR1	Full reimbursement flag	A flag indicating full reimbursement provided by the insurance company (I), i.e. for medicinal products, for which full reimbursement has been determined in compliance with Act No 48/2007, as amended. **J** – Full reimbursement flag for those cases where ORC <= UHR1.
Y	UHRPROC	Percentage reimbursement	The percentage of reimbursement stipulated by Decree of the Ministry of Health of the Czech Republic.
Z	DNC	Highest agreed price	Indication of the highest agreed price (X), in compliance with the agreement concluded by the health insurance company and the MA holder. Should the calculated ORC be lower than the highest agreed price notified by the insurance company, the X identification shall not be provided.
AA	UHR2	Increased reimbursement	The increased reimbursement of the medicinal product/food for special medical purposes established by SÚKL in compliance with Section 39b, paragraph 6 of Act No 48/1997 Coll.
AB	LIM2	Increased reimbursement reporting limit	The method of reporting the increased reimbursement of medicinal products/foods for special medical purposes to the health insurance company. The Czech version of the website provides an implemental index of status values for fields LIM1 and LIM2.
AC	OME2	Prescribing doctor's specialisation	Specification of prescription restriction, for increased reimbursement of medicinal products/foods for special medical purposes, based upon the specialisation of the prescribing doctor. For a single code of the medicinal product/food for special medical purposes it may assume several OME2 values. The Czech version of the website provides an implemental index of status values for fields OME1 and OME2.
AD	IND2	Indication restriction flag	Indication restriction (P), for increased reimbursement of medicinal products/foods for special medical purposes. An implemental index is available for indication prescription detail (indication or clinical status conditioning the reimbursement of

			the medicinal products/foods for special medical purposes).
AE	UPO2	Full reimbursement flag	A flag indicating full reimbursement provided by the insurance company (I), i.e. for medicinal products/foods for special medical purposes, for which full reimbursement has been determined in compliance with Act No 48/2007, as amended with the effective date of January 1 2008 *Note: where this has been applied only to the increased reimbursement*
AF	RS	Reference group	The relevant reference group of the medicinal product, where the medicinal product has been allocated a reference group by SÚKL when establishing the amount and conditions of reimbursement; it shall comprise of the relevant therapeutic group (TS), separation symbol (/), sequence of the subgroup of products which are similar or which can cause confusion in the RS (RS_P); RS stipulated by a Decree of the Ministry of Health of the Czech Republic on the basis of authorisation pursuant to Section 39c, paragraph 1 of Act No 48/1997 Coll.
AG	TS	Therapeutic group	The relevant therapeutic group of the medicinal product/food for special medical purposes, if it has been allocated a therapeutic group by SÚKL when establishing the amount and conditions of reimbursement; TS stipulated by a Decree of the Ministry of Health of the Czech Republic on the basis of authorisation pursuant to Section 39c, paragraph 1 of Act No 48/1997 Coll.
AH	TS_P	TS subgroup	The relevant subgroup of products which are similar or which can cause confusion within the TS of the medicinal product/food for special medical purposes, where an RS has been allocated by SÚKL when establishing the amount and conditions of reimbursement; TS_P stipulated by Decree of the Ministry of Health of the Czech Republic on the basis of authorisation pursuant to Section 39c, paragraph 1 of Act No 48/1997 Coll.
AI	ATC	Full ATC	Anatomical therapeutic chemical group
AJ	V_PLATOD	MA effective date	Effective date of the marketing authorisation
AK	V_PLATDO	MA expiry date	Expiry date of the marketing authorisation, unless unlimited validity has been granted pursuant to Section 34 of the Act on Pharmaceuticals
AL	NEOMEZ	Unlimited MA validity	Field to be completed (X) where unlimited validity of the marketing authorisation applies.
AM	HL_UV_OD	Placement on the market	Date of initial placement of supplies of the medicinal product on the market or reinstitution thereof, to be reported by the MA holder in compliance with Section 33 of the Act on Pharmaceuticals
AN	HL_UK_DO	Supply termination	Date of termination or discontinuation of supplies of the medicinal product onto the market, to be reported by the MA holder in compliance with Section 33 of the Act on Pharmaceuticals
AO	DDDM	Amount of active substance in DDD	Defined daily dose - the amount of active substance – information as per WHO
AP	DDDJ	Unit of active substance in DDD	Defined daily dose – unit – information as per WHO
AQ	DDDBAL	DDD count in pack of medicinal product	The number of defined daily doses in a pack - where DDD has been established by WHO
AR	ODTD	Usual daily therapeutic dose	The usual daily therapeutic dose
AS	ODTDJ	Unit of active substance amount in ODTD	The usual daily therapeutic dose – unit
AT	EKV	Basic reimbursement	The basic reimbursement of the active substance for the usual daily therapeutic dose, where it has been established by SÚKL in compliance with Section 39c, paragraphs 1 and 2 of Act No 48/1997 Coll.
AU	DAT_MCV	MCV Validity	Date of change to the determined maximum ex-factory price
AV	DAT_UHR	UHR Validity	Date of change to the determined amount and conditions of reimbursement
AW	ZAP1	Allowable extra payment	Allowable extra payment for UHR1, as per the communication of the Ministry of Health of the Czech Republic, stipulated in compliance with Section 16b, paragraph 1of Act No 48/1997 Coll.)
AX	ZAP2	Allowable extra payment for increased reimbursement	Allowable extra payment for UHR2, as per the communication of the Ministry of Health of the Czech Republic, stipulated in compliance with Section 16b, paragraph 1of Act No 48/1997 Coll.)

AY	NEZAP	Limit allowability symbol	A flag of the category of the pharmaceutical (non-allowability in respect of the limit) , as per the communication of the Ministry of Health of the Czech Republic, stipulated in compliance with Section 16b, paragraph 1of Act No 48/1997 Coll. An implemental index is available for the NEZAP 1 field.
AZ	ZPVYD	Method of dispensing	Classification of the product for dispensing: F – without medical prescription, O – restricted OTC, R – on medical prescription V – selected medicinal product Where foods for special medical purposes are concerned, the method of dispensing shall not be specified, as decision-making in respect of the method of dispensing of foods for special medical purposes is not within the powers of SÚKL.
BA	RP1		Spare field
BB	ORC	Reference price	Reference price: - Final price with a differentiated profit margin and with the deducted regulatory fee, including a 10% VAT. Where the regulatory fee is not deducted (LIM 1 assumes the values of H, U, K, O, T, B, S, A, D, Y, X, Q, R), this field shall show the value equivalent to the final price without the deduction. - Where the product is not fully reimbursed following the deduction, this field shall show the value equivalent to the final price without deduction - Where the health insurance company and the MA holder have concluded a highest price agreement in respect of the product, this field of the List shall show the agreed price, lower than ORC with the deduction. Where the calculated ORC is less than the agreed highest price notified by the insurance company, this field shall show the calculated ORC value.
BC	RP3		Spare field
BD	MFC	Final price	Final price – final price (with profit margin and VAT) without the deduction. For products with OP type of regulation the MFC value shall not be provided in the List.
BE	RP5		Spare field

The implemental indices for fields OME1, OME2, LIM1 and LIM2 are available in their Czech version only, from www.sukl.cz.